



Item 2.02 Results of Operations and Financial Condition.

On February 25, 2019, Endologix, Inc. (the “Company”) issued a press release to report its preliminary unaudited financial results for the fourth quarter and fiscal year ended December 31, 2018, as well as its financial guidance for the first quarter ended March 31, 2019 and full fiscal year ending December 31, 2019. The press release is furnished herewith as Exhibit 99.1.

The press release attached as Exhibit 99.1 is being furnished herewith and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, or the Securities Exchange Act of 1934, as amended, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number	Description
-------------------	-------------

<u>99.1</u>	Press Release Regarding Fourth Quarter and Fiscal Year 2018 Financial Results, dated February 25, 2019.
-------------	---

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ENDOLOGIX, INC.

Date: February 25, 2019 /s/ Vaseem Mahboob  
Vaseem Mahboob  
Chief Financial Officer  
(Principal Financial and Accounting Officer)

---

EXHIBIT INDEX

Exhibit Number	Description
-------------------	-------------

<u>99.1</u>	Press Release Regarding Fourth Quarter and Fiscal Year 2018 Financial Results, dated February 25, 2019.
-------------	---